Loading market dashboard
Solesence, Inc. Common Stock
SLSNConsumer DefensiveNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SPF-Infused Concealer Featuring Kleair, WHSPR, and Chromalüm Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill. , May 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that its prototype product, Day Mode Hero Concealer SPF 50, has won across three prototype product/chassis categories at the 2026 Cosmetics and Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin.
SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin
Solesence incurs a Q1 loss per share as shipment delays pressure revenues, even as gross margin improves and the company reaffirms its 2026 profitability targets.
The report, led by the United Kingdom's APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation.
Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript
Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.
New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment
ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2026 after the market opens on Tuesday, May 12, 2026, and host a conference call and webcast on the same date.
Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc James to its Board of Directors as an independent director, effective immediately.
Discover why Zacks issues an "Underperform" rating for Solesence, being the first on Wall Street to initiate coverage on the stock. Learn how margin pressure, cash flow weakness, rising leverage and execution challenges are weighing on growth.
Solesence, Inc. (SLSN) Q4 2025 Earnings Call Transcript
Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2025.
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 31, 2026, and host a conference call and webcast on the same date.
